{
  "trial_id": "NCT00252603",
  "overall_assessment": "likely_ineligible",
  "inclusion": [],
  "exclusion": [
    {
      "criterion": "past or present mental disorders: psychotic disorders, mood disorders, including bipolar disorders.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "significant self-injurious behavior (children who have caused visible harm to themselves).",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "active seizure disorder (seizures within the past six months).",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "clinically significant or unstable medical illness, including patients with current evidence of clinically significant hematopoietic, or cardiovascular disease.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "gastrointestinal, liver, kidney, or other known conditions which will presently interfere with the absorption, distribution, metabolism, or excretion of drugs, seizure disorders (active), cerebrovascular disease or brain trauma as etiology of autistic behavior.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "clinically significant unstable endocrine disorder, such as hypo- or hyperthyroidism or diabetes.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "recent history or presence of any form of malignancy.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "significant improvement of autism symptoms and behaviors to current medications or have only global autism ratings on the CGI of absent, minimal or mild severity, or who are more than minimally verbal.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "global autism ratings are assessed as being absent, minimal or mild.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "treatment within the previous 30 days with any drug known to have a well-defined potential for toxicity to a major organ.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "clinically significant abnormalities in laboratory tests or physical exam.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "likely to require any other psychotropic medication during the study, with the exception of clonidine for insomnia (started at least one month prior to entrance into the study), as well as anticonvulsants at a constant dose for stable seizure disorder or, unless otherwise permitted.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "unable to tolerate taper from psychoactive medication, if specified.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "history of hypersensitivity or severe side effects associated with the use of galantamine, or other acetylcholinesterase inhibitors.",
      "label": "triggers",
      "evidence": "none"
    },
    {
      "criterion": "prior treatment with galantamine of 4mg/day for 6 weeks.",
      "label": "triggers",
      "evidence": "none"
    }
  ],
  "notes": "Patient is a healthy woman, but has several exclusion criteria that make her likely ineligible.",
  "_meta": {
    "topic_id": "69",
    "trial_id": "NCT00252603",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}